{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:38:28Z","timestamp":1790836708043,"version":"4.1.0"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eiger"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Co-infection between hepatitis B virus (HBV) and hepatitis delta virus (HDV) causes the severest chronic hepatitis and is associated with a high risk of cirrhosis and hepatocellular carcinoma (HCC). The Global Health Sector Strategy on Viral Hepatitis called for the elimination of hepatitis (\u2212\u200965% mortality and\u2009\u2212\u200990% incidence) by 2030. Our aims were to summarize key points of knowledge and to identify the gaps that need to be addressed to mount a public health response to HDV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a current literature review in terms of epidemiology by WHO regions, genotypes distribution and their pathogenicity, factors associated with HDV infection, mortality due to HDV infection, testing strategies and treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Prevalence of infection and genotypes are heterogeneous distributed, with highest prevalence in foci around the Mediterranean, in the Middle East, and in Central, Northern Asia and Eastern Asia. Persons who inject drugs (PWID) and migrants from highly endemic areas are highly affected. While antibody detection tests are available, HDV RNA tests of current infection are not standardized nor widely available. The few therapeutic options, including lofartinib, are not widely available; however several new and promising agents have entered clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HDV infection is an poorly known cause of chronic liver disease. To mount a public health response, we need a better description of the HDV epidemic, standardized testing strategies and better treatment options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13690-021-00693-2","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T22:12:14Z","timestamp":1634595134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response?"],"prefix":"10.1186","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4416-2912","authenticated-orcid":false,"given":"Tomoyuki","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumie","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvan J.-F.","family":"Hutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hande","family":"Harmanci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa","family":"Easterbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"van Holten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ena Oghenekaro","family":"Oru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihan","family":"Yurdaydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bulterys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"issue":"6137","key":"693_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/329343a0","volume":"329","author":"S Makino","year":"1986","unstructured":"Makino S, Chang MF, Shieh CK, Kamahora T, Vannier DM, Govindarajan S, et al. Molecular cloning and sequencing of a human hepatitis delta virus RNA. Nature. 1986;329(6137):343\u20136. https:\/\/doi.org\/10.1038\/329343a0.","journal-title":"Nature"},{"key":"693_CR2","volume-title":"Global hepatitis report","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Global hepatitis report. Geneva: World Health Organization; 2017."},{"key":"693_CR3","doi-asserted-by":"publisher","first-page":"S212","DOI":"10.1016\/S0168-8278(03)00331-3","volume":"39","author":"P Farci","year":"2003","unstructured":"Farci P. Delta hepatitis: an update. J Hepatol. 2003;39:S212\u20139. https:\/\/doi.org\/10.1016\/S0168-8278(03)00331-3.","journal-title":"J Hepatol"},{"key":"693_CR4","doi-asserted-by":"publisher","first-page":"a021576","DOI":"10.1101\/cshperspect.a021576","volume":"5","author":"M Rizzetto","year":"2015","unstructured":"Rizzetto M, Hepatitis D. Virus: introduction and epidemiology. Cold Spring Harb Perspect Med. 2015;5:a021576.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"693_CR5","volume-title":"Global health sector strategy on viral hepatitis 2016-2021","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Geneva: World Health Organization; 2016."},{"key":"693_CR6","doi-asserted-by":"publisher","unstructured":"Chen HY, Shen DT, Ji DZ, Han PC, Zhang WM, Ma JF, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2018. https:\/\/doi.org\/10.1136\/gutjnl-2018-316601.","DOI":"10.1136\/gutjnl-2018-316601"},{"key":"693_CR7","doi-asserted-by":"publisher","unstructured":"Miao Z, Zhang S, Ou X, Li S, Ma Z, Wang W, et al. Estimating the global prevalence, disease progression and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2019. https:\/\/doi.org\/10.1093\/infdis\/jiz633.","DOI":"10.1093\/infdis\/jiz633"},{"key":"693_CR8","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u201399.","journal-title":"Hepatology"},{"issue":"1","key":"693_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","volume":"57","author":"European Association For The Study Of The Liver","year":"2012","unstructured":"European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167\u201385. https:\/\/doi.org\/10.1016\/j.jhep.2012.02.010.","journal-title":"J Hepatol"},{"key":"693_CR10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver; European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver; European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370\u201398.","journal-title":"J Hepatol"},{"issue":"1","key":"693_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1\u201398. https:\/\/doi.org\/10.1007\/s12072-015-9675-4.","journal-title":"Hepatol Int"},{"issue":"9","key":"693_CR12","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/MCG.0000000000000647","volume":"50","author":"J Feld","year":"2016","unstructured":"Feld J, Janssen HL, Abbas Z, Elewaut A, Ferenci P, Isakov V, et al. World gastroenterology organisation global guideline hepatitis B: September 2015. J Clin Gastroenterol. 2016;50(9):691\u2013703. https:\/\/doi.org\/10.1097\/MCG.0000000000000647.","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"693_CR13","doi-asserted-by":"publisher","first-page":"e8210","DOI":"10.5812\/hepatmon.8210","volume":"13","author":"N Amini","year":"2013","unstructured":"Amini N, Alavian SM, Kabir A, Aalaei-Andabili SH, Saiedi Hosseini SY, Rizzetto M. Prevalence of hepatitis d in the eastern mediterranean region: systematic review and meta analysis. Hepat Mon. 2013;13(1):e8210. https:\/\/doi.org\/10.5812\/hepatmon.8210.","journal-title":"Hepat Mon"},{"issue":"10","key":"693_CR14","doi-asserted-by":"publisher","first-page":"e992","DOI":"10.1016\/S2214-109X(17)30298-X","volume":"5","author":"AJ Stockdale","year":"2017","unstructured":"Stockdale AJ, Chaponda M, Beloukas A, Phillips RO, Matthews PC, Papadimitropoulos A, et al. Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(10):e992\u2013e1003. https:\/\/doi.org\/10.1016\/S2214-109X(17)30298-X.","journal-title":"Lancet Glob Health"},{"key":"693_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jcv.2015.02.011","volume":"66","author":"K El Bouzidi","year":"2015","unstructured":"El Bouzidi K, Elamin W, Kranzer K, Irish DN, Ferns B, Kennedy P, et al. Hepatitis delta virus testing, epidemiology and management: a multicentre cross-sectional study of patients in London. J Clin Virol. 2015;66:33\u20137. https:\/\/doi.org\/10.1016\/j.jcv.2015.02.011.","journal-title":"J Clin Virol"},{"key":"693_CR16","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.12688\/f1000research.11796.1","volume":"6","author":"C Yurdaydin","year":"2017","unstructured":"Yurdaydin C. Recent advances in managing hepatitis D. F1000Res. 2017;6:1596.","journal-title":"F1000Res"},{"issue":"3","key":"693_CR17","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","volume":"73","author":"AJ Stockdale","year":"2020","unstructured":"Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020 Sep;73(3):523\u201332. https:\/\/doi.org\/10.1016\/j.jhep.2020.04.008.","journal-title":"J Hepatol"},{"key":"693_CR18","volume-title":"Media Centre","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Hepatitis D: Fact Sheet. In: Media Centre. Geneva: World Health Organization; 2017. [cited 2018 Apr 16]. Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/hepatitis-d\/en\/."},{"key":"693_CR19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s12879-017-2619-y","volume":"17","author":"H Perazzo","year":"2017","unstructured":"Perazzo H, Pacheco AG, Luz PM, Castro R, Hyde C, Fittipaldi J, et al. Age-standardized mortality rates related to viral hepatitis in Brazil. BMC Infect Dis. 2017;17:527. https:\/\/doi.org\/10.1186\/s12879-017-2619-y.","journal-title":"BMC Infect Dis"},{"key":"693_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/1471-2334-14-94","volume":"14","author":"MA Crispim","year":"2014","unstructured":"Crispim MA, Fraiji NA, Campello SC, Schriefer NA, Stefani MM, Kiesslich D. Molecular epidemiology of hepatitis B and hepatitis delta viruses circulating in the Western Amazon region, North Brazil. BMC Infect Dis. 2014;14:94. https:\/\/doi.org\/10.1186\/1471-2334-14-94.","journal-title":"BMC Infect Dis"},{"key":"693_CR21","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12985-015-0402-5","volume":"12","author":"VD di Filippo","year":"2015","unstructured":"di Filippo VD, Cortes-Mancera F, Payares E, Montes N, de la Hoz F, Arbelaez MP, et al. Hepatitis D virus and hepatitis B virus infection in Amerindian communities of the Amazonas state, Colombia. Virol J. 2015;12:172. https:\/\/doi.org\/10.1186\/s12985-015-0402-5.","journal-title":"Virol J"},{"key":"693_CR22","doi-asserted-by":"publisher","unstructured":"Safaie P, Razeghi S, Rouster SD, Privitera I, Sherman KE. Hepatitis D diagnostics:utilization and testing in the united states. Virus Res. 2018. https:\/\/doi.org\/10.1016\/j.virusres.2018.03.013 [Epub ahead of print].","DOI":"10.1016\/j.virusres.2018.03.013"},{"issue":"6","key":"693_CR23","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jhep.2014.05.041","volume":"61","author":"WS Braga","year":"2014","unstructured":"Braga WS, de Oliveira CM, de Ara\u00fajo JR, Castilho Mda C, Rocha JM, Gimaque JB, et al. Chronic HDV\/HBV co-infection: predictors of disease stage---a case series of HDV-3 patients. J Hepatol. 2014;61(6):1205\u201311. https:\/\/doi.org\/10.1016\/j.jhep.2014.05.041.","journal-title":"J Hepatol"},{"issue":"1","key":"693_CR24","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/1743-422X-8-420","volume":"8","author":"AU Khan","year":"2011","unstructured":"Khan AU, Waqar M, Akram M, Zaib M, Wasim M, Ahmad S, et al. True prevalence of twin HDV-HBV infection in Pakistan: a molecular approach. Virol J. 2011;8(1):420. https:\/\/doi.org\/10.1186\/1743-422X-8-420.","journal-title":"Virol J"},{"key":"693_CR25","doi-asserted-by":"publisher","first-page":"413","DOI":"10.15403\/jgld.2014.1121.244.dtv","volume":"24","author":"L Gheorghe","year":"2015","unstructured":"Gheorghe L, Csiki IE, Iacob S, Gheorghe C, Trifan A, Grigorescu M, et al. Hepatitis delta virus infection in Romania: prevalence and risk factors. J Gastrointestin Liver Dis. 2015;24:413\u201321.","journal-title":"J Gastrointestin Liver Dis"},{"issue":"2","key":"693_CR26","doi-asserted-by":"publisher","first-page":"415","DOI":"10.5114\/aoms.2015.52030","volume":"12","author":"AC Dulger","year":"2016","unstructured":"Dulger AC, Suvak B, Gonullu H, Gonullu E, Gultepe B, Ayd\u0131n \u0130, et al. High prevalence of chronic hepatitis D virus infection in eastern Turkey: urbanization of the disease. Arch Med Sci. 2016;12(2):415\u201320. https:\/\/doi.org\/10.5114\/aoms.2015.52030.","journal-title":"Arch Med Sci"},{"key":"693_CR27","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.transci.2014.03.005","volume":"50","author":"B Uzun","year":"2014","unstructured":"Uzun B, \u015eener AG, G\u00fcng\u00f6r S, Af\u015far I, Demirci M. Evaluation of hepatitis delta virus (HDV) infection in blood donors in western Turkey. Transfus Apher Sci. 2014;50:388\u201391.","journal-title":"Transfus Apher Sci"},{"key":"693_CR28","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1099\/0022-1317-82-11-2709","volume":"82","author":"V Ivaniushina","year":"2001","unstructured":"Ivaniushina V, Radjef N, Alexeeva M, Gault E, Semenov S, Salhi M, et al. Hepatitis delta virus genotypes I and II cocirculate in an endemic area of Yakutia, Russia. J Gen Virol. 2001;82:2709\u201318.","journal-title":"J Gen Virol"},{"key":"693_CR29","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/j.1365-2893.2009.01159.x","volume":"17","author":"ML B\u00f8rresen","year":"2010","unstructured":"B\u00f8rresen ML, Olsen OR, Ladefoged K, McMahon BJ, Hjuler T, Panum I, et al. Hepatitis D outbreak among children in a hepatitis B hyper-endemic settlement in Greenland. J Viral Hepat. 2010;17:162\u201370.","journal-title":"J Viral Hepat"},{"key":"693_CR30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1046\/j.1365-2893.1997.00063.x","volume":"4","author":"BC Langer","year":"1997","unstructured":"Langer BC, Fr\u00f6sner GG, von Brunn A. Epidemiological study of viral hepatitis types A, B, C, D and E among Inuits in West Greenland. J Viral Hepat. 1997;4:339\u201349.","journal-title":"J Viral Hepat"},{"issue":"6","key":"693_CR31","doi-asserted-by":"publisher","first-page":"692","DOI":"10.3109\/00365521.2011.634026","volume":"47","author":"KF Rex","year":"2012","unstructured":"Rex KF, Krarup HB, Laurberg P, Andersen S. Population-based comparative epidemiological survey of hepatitis B, D, and C among Inuit migrated to Denmark and in high endemic Greenland. Scand J Gastroenterol. 2012;47(6):692\u2013701. https:\/\/doi.org\/10.3109\/00365521.2011.634026.","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"693_CR32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1055\/s-0032-1323626","volume":"32","author":"M Rizzetto","year":"2012","unstructured":"Rizzetto M, Ciancio A. Epidemiology of hepatitis D. Semin Liver Dis. 2012;32(3):211\u20139. https:\/\/doi.org\/10.1055\/s-0032-1323626.","journal-title":"Semin Liver Dis"},{"key":"693_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/tropej\/49.6.371","volume":"49","author":"H Zaki","year":"2003","unstructured":"Zaki H, Darmstadt GL, Baten A, Ahsan CR, Saha SK. Seroepidemiology of hepatitis B and delta virus infections in Bangladesh. J Trop Pediatr. 2003;49:371\u20134.","journal-title":"J Trop Pediatr"},{"key":"693_CR34","first-page":"254","volume":"122","author":"P Chakraborty","year":"2005","unstructured":"Chakraborty P, Kailash U, Jain A, Goyal R, Gupta RK, Das BC, et al. Seroprevalence of hepatitis D virus in patients with hepatitis B virus-related liver diseases. Indian J Med Res. 2005;122:254\u20137.","journal-title":"Indian J Med Res"},{"key":"693_CR35","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00705-009-0406-9","volume":"154","author":"Mulyanto","year":"2009","unstructured":"Mulyanto, Depamede SN, Surayah K, Tsuda F, Ichiyama K, Takahashi M, et al. A nationwide molecular epidemiological study on hepatitis B virus in Indonesia: identification of two novel subgenotypes, B8 and C7. Arch Virol. 2009;154:1047\u201359.","journal-title":"Arch Virol"},{"key":"693_CR36","first-page":"837","volume":"33","author":"S Louisirirotchanakul","year":"2002","unstructured":"Louisirirotchanakul S, Myint KS, Srimee B, Kanoksinsombat C, Khamboonruang C, Kunstadter P, et al. The prevalence of viral hepatitis among the Hmong people of northern Thailand. Southeast Asian J Trop Med Public Health. 2002;33:837\u201344.","journal-title":"Southeast Asian J Trop Med Public Health"},{"issue":"1","key":"693_CR37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5005\/jp-journals-10018-1215","volume":"7","author":"O Baatarkhuu","year":"2017","unstructured":"Baatarkhuu O, Uugantsetseg G, Munkh-Orshikh D, Naranzul N, Badamjav S, Tserendagva D, et al. Viral hepatitis and liver diseases in Mongolia. Hepato-Gastroenterol. 2017;7(1):68\u201372. https:\/\/doi.org\/10.5005\/jp-journals-10018-1215.","journal-title":"Hepato-Gastroenterol"},{"issue":"6","key":"693_CR38","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/hep.28957","volume":"66","author":"X Chen","year":"2017","unstructured":"Chen X, Oidovsambuu O, Liu P, Grosely R, Elazar M, Winn VD, et al. A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians. Hepatology. 2017;66(6):1739\u201349. https:\/\/doi.org\/10.1002\/hep.28957.","journal-title":"Hepatology"},{"key":"693_CR39","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3748\/wjg.v16.i5.554","volume":"16","author":"Z Abbas","year":"2010","unstructured":"Abbas Z, Jafri W, Raza S. Hepatitis D: Scenario in the Asia-Pacific region. World J Gastroenterol. 2010;16:554\u201362. https:\/\/doi.org\/10.3748\/wjg.v16.i5.554.","journal-title":"World J Gastroenterol"},{"key":"693_CR40","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1002\/hep.27742","volume":"61","author":"HH Lin","year":"2015","unstructured":"Lin HH, Lee SS, Yu ML, Chang TT, Su CW, Hu BS, et al. Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program. Hepatology. 2015;61:1870\u20139. https:\/\/doi.org\/10.1002\/hep.27742.","journal-title":"Hepatology"},{"issue":"4","key":"693_CR41","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1440-1746.1997.tb00425.x","volume":"12","author":"H Sakugawa","year":"1997","unstructured":"Sakugawa H, Nakasone H, Shokita H, Kawakami Y, Nakachi N, Adaniya H, et al. Seroepidemiological study on hepatitis delta virus infection in the Irabu Islands, Okinawa, Japan. J Gastroenterol Hepatol. 1997;12(4):299\u2013304. https:\/\/doi.org\/10.1111\/j.1440-1746.1997.tb00425.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"693_CR42","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/(SICI)1096-9071(199908)58:4<366::AID-JMV8>3.0.CO;2-X","volume":"58","author":"H Sakugawa","year":"1999","unstructured":"Sakugawa H, Nakasone H, Nakayoshi T, Kawakami Y, Miyazato S, Kinjo F, et al. Hepatitis delta virus genotype IIb predominates in an endemic area, Okinawa, Japan. J Med Virol. 1999;58:366\u201372.","journal-title":"J Med Virol"},{"issue":"1","key":"693_CR43","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jcv.2014.05.021","volume":"61","author":"M Han","year":"2014","unstructured":"Han M, Littlejohn M, Yuen L, Edwards R, Devi U, Bowden S, et al. Molecular epidemiology of hepatitis delta virus in the Western Pacific region. J Clin Virol. 2014;61(1):34\u20139. https:\/\/doi.org\/10.1016\/j.jcv.2014.05.021.","journal-title":"J Clin Virol"},{"key":"693_CR44","first-page":"89","volume":"364","author":"M Dimitrakakis","year":"1991","unstructured":"Dimitrakakis M, Gust I. HDV infection in the Western Pacific region. Prog Clin Biol Res. 1991;364:89\u201396.","journal-title":"Prog Clin Biol Res"},{"issue":"2","key":"693_CR45","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/jmv.1890290210","volume":"29","author":"CJ Tibbs","year":"1989","unstructured":"Tibbs CJ. Delta hepatitis in Kiribati: a pacific focus. J Med Virol. 1989;29(2):130\u20132. https:\/\/doi.org\/10.1002\/jmv.1890290210.","journal-title":"J Med Virol"},{"key":"693_CR46","doi-asserted-by":"publisher","first-page":"e78094","DOI":"10.1371\/journal.pone.0078094","volume":"8","author":"BT Sy","year":"2013","unstructured":"Sy BT, Ratsch BA, Toan NL, le Song H, Wollboldt C, Bryniok A, et al. High prevalence and significance of hepatitis D virus infection among treatment-na\u00efve HBsAg-positive patients in Northern Vietnam. PLoS One. 2013;8:e78094. https:\/\/doi.org\/10.1371\/journal.pone.0078094.","journal-title":"PLoS One"},{"issue":"4","key":"693_CR47","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/jmv.10427","volume":"70","author":"N Saudy","year":"2003","unstructured":"Saudy N, Sugauchi F, Tanaka Y, Suzuki S, Aal AA, Zaid MA, et al. Genotypes and phylogenetic characterization of hepatitis B and delta viruses in Egypt. J Med Virol. 2003;70(4):529\u201336. https:\/\/doi.org\/10.1002\/jmv.10427.","journal-title":"J Med Virol"},{"key":"693_CR48","first-page":"392","volume":"11","author":"M Takahashi","year":"2004","unstructured":"Takahashi M, Nishizawa T, Gotanda Y, Tsuda F, Komatsu F, Kawabata T, et al. High prevalence of antibodies to hepatitis A and E viruses and viremia of hepatitis B, C, and D viruses among apparently healthy populations in Mongolia. Clin Diagn Lab Immunol. 2004;11:392\u20138.","journal-title":"Clin Diagn Lab Immunol"},{"issue":"5","key":"693_CR49","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/jmv.20574","volume":"78","author":"B Tsatsralt-Od","year":"2006","unstructured":"Tsatsralt-Od B, Takahashi M, Endo K, Buyankhuu O, Baatarkhuu O, Nishizawa T, et al. Infection with hepatitis A, B, C, and delta viruses among patients with acute hepatitis in Mongolia. J Med Virol. 2006;78(5):542\u201350. https:\/\/doi.org\/10.1002\/jmv.20574.","journal-title":"J Med Virol"},{"issue":"2","key":"693_CR50","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/jmv.21057","volume":"80","author":"A Khan","year":"2008","unstructured":"Khan A, Kurbanov F, Tanaka Y, Elkady A, Sugiyama M, Dustov A, et al. Epidemiological and clinical evaluation of hepatitis B, hepatitis C, and delta hepatitis viruses in Tajikistan. J Med Virol. 2008;80(2):268\u201376. https:\/\/doi.org\/10.1002\/jmv.21057.","journal-title":"J Med Virol"},{"issue":"12","key":"693_CR51","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1002\/jmv.21326","volume":"80","author":"SR Mohebbi","year":"2008","unstructured":"Mohebbi SR, Zali N, Derakhshan F, Tahami A, Mashayekhi R, Amini-Bavil-Olyaee S, et al. Molecular epidemiology of hepatitis delta virus (HDV) in Iran: a preliminary report. J Med Virol. 2008;80(12):2092\u20139. https:\/\/doi.org\/10.1002\/jmv.21326.","journal-title":"J Med Virol"},{"key":"693_CR52","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1007\/s00705-011-1120-y","volume":"156","author":"I Celik","year":"2011","unstructured":"Celik I, Karatayli E, Cevik E, Kabak\u00e7i SG, Karatayli SC, Din\u00e7 B, et al. Complete genome sequences and phylogenetic analysis of hepatitis delta viruses isolated from nine Turkish patients. Arch Virol. 2011;156:2215\u201320.","journal-title":"Arch Virol"},{"key":"693_CR53","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/1743-422X-9-162","volume":"9","author":"S Perveen","year":"2012","unstructured":"Perveen S, Nasir MI, Shahid SM, Azhar A, Khan OY. Phylogenetic analysis of HDV isolates from HBsAg positive patients in Karachi, Pakistan. Virol J. 2012;9:162. https:\/\/doi.org\/10.1186\/1743-422X-9-162.","journal-title":"Virol J"},{"key":"693_CR54","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3855\/jidc.3910","volume":"8","author":"Y Bulut","year":"2014","unstructured":"Bulut Y, Bahcecioglu IH, Aygun C, Oner PD, Ozercan I, Demirdag K. High genetic diversity of hepatitis delta virus in eastern Turkey. J Infect Dev Ctries. 2014;8:74\u20138.","journal-title":"J Infect Dev Ctries"},{"issue":"3","key":"693_CR55","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/apm.12137","volume":"122","author":"MS Attaran","year":"2014","unstructured":"Attaran MS, Sharifi Z, Hosseini SM, Samei S, Ataee Z. Prevalence of hepatitis B and hepatitis D coinfection in asymptomatic blood donors in Iran. APMIS. 2014;122(3):243\u20137. https:\/\/doi.org\/10.1111\/apm.12137.","journal-title":"APMIS"},{"key":"693_CR56","doi-asserted-by":"publisher","first-page":"510. e11","DOI":"10.1016\/j.cmi.2014.12.008","volume":"21","author":"E Shirvani-Dastgerdi","year":"2015","unstructured":"Shirvani-Dastgerdi E, Amini-Bavil-Olyaee S, Alavian SM, Trautwein C, Tacke F. Comprehensive analysis of mutations in the hepatitis delta virus genome based on full-length sequencing in a nationwide cohort study and evolutionary pattern during disease progression. Clin Microbiol Infect. 2015;21:510. e11\u201323. https:\/\/doi.org\/10.1016\/j.cmi.2014.12.008 Epub 2014 Dec 26.","journal-title":"Clin Microbiol Infect"},{"key":"693_CR57","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jcv.2015.10.002","volume":"72","author":"L Yacoubi","year":"2015","unstructured":"Yacoubi L, Brichler S, Mansour W, Le Gal F, Hammami W, Sadraoui A, et al. Molecular epidemiology of hepatitis B and Delta virus strains that spread in the Mediterranean North East Coast of Tunisia. J Clin Virol. 2015;72:126\u201332. https:\/\/doi.org\/10.1016\/j.jcv.2015.10.002.","journal-title":"J Clin Virol"},{"issue":"6","key":"693_CR58","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1053\/j.gastro.2006.01.035","volume":"130","author":"CW Su","year":"2006","unstructured":"Su CW, Huang YH, Huo TI, Shih HH, Sheen IJ, Chen SW, et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology. 2006;130(6):1625\u201335. https:\/\/doi.org\/10.1053\/j.gastro.2006.01.035.","journal-title":"Gastroenterology"},{"key":"693_CR59","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijid.2016.03.017","volume":"46","author":"LM Borzacov","year":"2016","unstructured":"Borzacov LM, de Figueiredo Nicolete LD, Souza LF, Dos Santos AO, Vieira DS, Salcedo JM. Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir. Int J Infect Dis. 2016;46:82\u20138.","journal-title":"Int J Infect Dis"},{"key":"693_CR60","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1099\/vir.0.19499-0","volume":"84","author":"H Watanabe","year":"2003","unstructured":"Watanabe H, Nagayama K, Enomoto N, Chinzei R, Yamashiro T, Izumi N, et al. Chronic hepatitis delta virus infection with genotype IIb variant is correlated with progressive liver disease. J Gen Virol. 2003;84:3275\u201389.","journal-title":"J Gen Virol"},{"key":"693_CR61","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.3201\/eid1209.060112","volume":"12","author":"F Le Gal","year":"2006","unstructured":"Le Gal F, Gault E, Ripault MP, Serpaggi J, Trinchet JC, Gordien E, et al. Eighth major clade for hepatitisdelta virus. Emerg Infect Dis. 2006;12:1447\u201350.","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"693_CR62","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1128\/JVI.78.5.2537-2544.2004","volume":"78","author":"N Radjef","year":"2004","unstructured":"Radjef N, Gordien E, Ivaniushina V, Gault E, Ana\u00efs P, Drugan T, et al. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol. 2004;78(5):2537\u201344. https:\/\/doi.org\/10.1128\/JVI.78.5.2537-2544.2004.","journal-title":"J Virol"},{"key":"693_CR63","first-page":"S783","volume":"68","author":"A Gerber","year":"2018","unstructured":"Gerber A, Gal FL, Dziri S, Alloui C, Roulot D, Abdesselam ZB, et al. Molecular diversity of HDV strains that spread in France: a study of 2224 clinical strains prospectively collected during fifteen years. J Hepatol. 2018;68:S783.","journal-title":"J Hepatol"},{"key":"693_CR64","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1111\/jvh.27_12922","volume":"25","author":"M Spaan","year":"2018","unstructured":"Spaan M, Carey I, Bruce M, Shang D, Dusheiko G, Agarwal K. Are hepatitis delta virus (HDV) genotypes important to determine the disease progression and therapy responses? J Viral Hepat. 2018;25:S21.","journal-title":"J Viral Hepat"},{"key":"693_CR65","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1086\/655808","volume":"202","author":"LM Kucirka","year":"2010","unstructured":"Kucirka LM, Farzadegan H, Feld JJ, Mehta SH, Winters M, Glenn JS, et al. Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis. 2010;202:845\u201352.","journal-title":"J Infect Dis"},{"issue":"3","key":"693_CR66","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jhep.2015.04.025","volume":"63","author":"T Kushner","year":"2015","unstructured":"Kushner T, Serper M, Kaplan DE. Delta hepatitis within the veterans affairs medical system in the United States: prevalence, risk factors, and outcomes. J Hepatol. 2015;63(3):586\u201392. https:\/\/doi.org\/10.1016\/j.jhep.2015.04.025.","journal-title":"J Hepatol"},{"key":"693_CR67","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/jmv.21078","volume":"80","author":"TJ Cross","year":"2008","unstructured":"Cross TJ, Rizzi P, Horner M, Jolly A, Hussain MJ, Smith HM, et al. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol. 2008;80:277\u201382.","journal-title":"J Med Virol"},{"issue":"18","key":"693_CR68","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1001\/jama.1992.03480180063030","volume":"267","author":"L Rosenblum","year":"1992","unstructured":"Rosenblum L, Darrow W, Witte J, Cohen J, French J, Gill PS, et al. Sexual practices in the transmission of hepatitis B virus and prevalence of hepatitis delta virus infection in female prostitutes in the United States. JAMA. 1992;267(18):2477\u201381. https:\/\/doi.org\/10.1001\/jama.1992.03480180063030.","journal-title":"JAMA"},{"issue":"2","key":"693_CR69","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jcv.2013.11.016","volume":"59","author":"A Servant-Delmas","year":"2014","unstructured":"Servant-Delmas A, Le Gal F, Gallian P, Gordien E, Laperche S. Increasing prevalence of HDV\/HBV infection over 15 years in France. J Clin Virol. 2014;59(2):126\u20138. https:\/\/doi.org\/10.1016\/j.jcv.2013.11.016.","journal-title":"J Clin Virol"},{"issue":"5","key":"693_CR70","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jhep.2013.07.005","volume":"59","author":"EK Manesis","year":"2013","unstructured":"Manesis EK, Vourli G, Dalekos G, Vasiliadis T, Manolaki N, Hounta A, et al. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. J Hepatol. 2013;59(5):949\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2013.07.005.","journal-title":"J Hepatol"},{"key":"693_CR71","first-page":"114","volume":"39","author":"E Sagnelli","year":"2016","unstructured":"Sagnelli E, Taliani G, Castelli F, Bartolozzi D, Cacopardo B, Armignacco O, et al. Chronic HBV infection in pregnant immigrants: a multicenter study of the Italian Society of Infectious and Tropical Diseases. New Microbiol. 2016;39:114\u20138.","journal-title":"New Microbiol"},{"key":"693_CR72","doi-asserted-by":"publisher","first-page":"789","DOI":"10.4269\/ajtmh.12-0319","volume":"88","author":"P Rivas","year":"2013","unstructured":"Rivas P, Herrero MD, Poveda E, Madej\u00f3n A, Trevi\u00f1o A, Guti\u00e9rrez M, et al. Hepatitis B, C, and D and HIV infections among immigrants from Equatorial Guinea living in Spain. Am J Trop Med Hyg. 2013;88:789\u201394.","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"693_CR73","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrgastro.2009.205","volume":"7","author":"H Wedemeyer","year":"2010","unstructured":"Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol. 2010;7(1):31\u201340. https:\/\/doi.org\/10.1038\/nrgastro.2009.205.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"693_CR74","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1016\/S2214-109X(16)30143-7","volume":"4","author":"M Plummer","year":"2016","unstructured":"Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4(9):e609\u201316. https:\/\/doi.org\/10.1016\/S2214-109X(16)30143-7.","journal-title":"Lancet Glob Health"},{"issue":"12","key":"693_CR75","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1002\/ijc.31280","volume":"142","author":"D Maucort-Boulch","year":"2018","unstructured":"Maucort-Boulch D, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. Int J Cancer. 2018;142(12):2471\u20137. https:\/\/doi.org\/10.1002\/ijc.31280.","journal-title":"Int J Cancer"},{"key":"693_CR76","volume-title":"Summary tables of mortality estimates by cause, age and sex, globally and by region, 2000\u20132016","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Summary tables of mortality estimates by cause, age and sex, globally and by region, 2000\u20132016. Geneva: World Health Organization; 2018. http:\/\/www.who.int\/healthinfo\/global_burden_disease\/en\/"},{"issue":"6","key":"693_CR77","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/jvh.13081","volume":"26","author":"C Yurdaydin","year":"2019","unstructured":"Yurdaydin C. New treatment options for delta virus: is a cure in sight? J Viral Hepat. 2019;26(6):618\u201326. https:\/\/doi.org\/10.1111\/jvh.13081.","journal-title":"J Viral Hepat"},{"key":"693_CR78","volume-title":"Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015."},{"issue":"2","key":"693_CR79","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/hep.28876","volume":"65","author":"A Wranke","year":"2017","unstructured":"Wranke A, Serrano BC, Heidrich B, Kirschner J, Bremer B, Lehmann P, et al. Antiviral treatment and liver-related complications in hepatitis delta. Hepatology. 2017;65(2):414\u201325. https:\/\/doi.org\/10.1002\/hep.28876.","journal-title":"Hepatology"},{"issue":"7","key":"693_CR80","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/j.1478-3231.2006.01279.x","volume":"26","author":"A Erhardt","year":"2006","unstructured":"Erhardt A, Gerlich W, Starke C, Wend U, Donner A, Sagir A, et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int. 2006;26(7):805\u201310. https:\/\/doi.org\/10.1111\/j.1478-3231.2006.01279.x.","journal-title":"Liver Int"},{"issue":"3","key":"693_CR81","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/hep.21296","volume":"44","author":"GA Niro","year":"2006","unstructured":"Niro GA, Ciancio A, Gaeta GB, Smedile A, Marrone A, Olivero A, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. 2006;44(3):713\u201320. https:\/\/doi.org\/10.1002\/hep.21296.","journal-title":"Hepatology"},{"key":"693_CR82","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa0912696","volume":"364","author":"H Wedemeyer","year":"2011","unstructured":"Wedemeyer H, Yurdayd\u00ecn C, Dalekos GN, Erhardt A, \u00c7akalo\u011flu Y, De\u011fertekin H, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364:322\u201331.","journal-title":"N Engl J Med"},{"issue":"3","key":"693_CR83","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/hep.21325","volume":"44","author":"C Castelnau","year":"2006","unstructured":"Castelnau C, Le Gal F, Ripault MP, Gordien E, Martinot-Peignoux M, Boyer N, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology. 2006;44(3):728\u201335. https:\/\/doi.org\/10.1002\/hep.21325.","journal-title":"Hepatology"},{"key":"693_CR84","first-page":"206","volume":"79","author":"B Yilmaz","year":"2016","unstructured":"Yilmaz B, Can G, Ucmak F, Arslan AO, Solmaz I, Unlu O, et al. Polymorphisms in the IL28B gene (rs12979860, rs8099917) and the virological response to pegylated interferon therapy in hepatitis D virus patients. Acta Gastroenterol Belg. 2016;79:206\u201310.","journal-title":"Acta Gastroenterol Belg"},{"key":"693_CR85","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1055\/s-0032-1323629","volume":"32","author":"C Yurdaydin","year":"2012","unstructured":"Yurdaydin C. Treatment of chronic delta hepatitis. Semin Liver Dis. 2012;32:237\u201344.","journal-title":"Semin Liver Dis"},{"key":"693_CR86","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/135965350801300110","volume":"13","author":"J Sheldon","year":"2008","unstructured":"Sheldon J, Ramos B, Toro C, R\u00edos P, Mart\u00ednez-Alarc\u00f3n J, Bottecchia M, et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients? Antivir Ther. 2008;13:97\u2013102.","journal-title":"Antivir Ther"},{"key":"693_CR87","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1093\/cid\/ciu167","volume":"58","author":"JV Fern\u00e1ndez-Montero","year":"2014","unstructured":"Fern\u00e1ndez-Montero JV, Vispo E, Barreiro P, Sierra-Enguita R, de Mendoza C, Labarga P, et al. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. Clin Infect Dis. 2014;58:1549\u201353.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"693_CR88","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1089\/aid.2013.0008","volume":"29","author":"A Boyd","year":"2013","unstructured":"Boyd A, Miailhes P, Brichler S, Scholt\u00e8s C, Maylin S, Delaugerre C, et al. Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients. AIDS Res Hum Retrovir. 2013;29(12):1535\u201340. https:\/\/doi.org\/10.1089\/aid.2013.0008.","journal-title":"AIDS Res Hum Retrovir"},{"key":"693_CR89","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1093\/cid\/cix125","volume":"64","author":"C B\u00e9guelin","year":"2017","unstructured":"B\u00e9guelin C, Friolet N, Moradpour D, Sahli R, Suter-Riniker F, L\u00fcthi A, et al. Impact of tenofovir on hepatitis delta virus replication in the Swiss human immunodeficiency virus cohort study. Clin Infect Dis. 2017;64:1275\u20138.","journal-title":"Clin Infect Dis"},{"key":"693_CR90","doi-asserted-by":"publisher","first-page":"FS507","DOI":"10.1016\/S0168-8278(18)31261-3","volume":"68","author":"A Wranke","year":"2018","unstructured":"Wranke A, Yurdaydin C, Heidrich B, Kalliopi Z, Yalcin K, Fehmi Z, et al. A virological response to PEG-IFNa treatment of hepatitis delta is associated with an improved clinical long-term outcome: 10 years follow-up of the HIDIT-1 study. J Hepatol. 2018;68:FS507.","journal-title":"J Hepatol"},{"key":"693_CR91","doi-asserted-by":"crossref","first-page":"222A","DOI":"10.1002\/hep.26274","volume":"58","author":"H Wedemeyer","year":"2013","unstructured":"Wedemeyer H, Yurdaydin C, Ernst S, Caruntu FA, Curescu MG, Kendal YK, et al. 96 weeks of pegylated-Interferonalpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study. Hepatology. 2013;58:222A\u20133A.","journal-title":"Hepatology"},{"issue":"4","key":"693_CR92","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1440-1746.2006.04082.x","volume":"21","author":"B Canbakan","year":"2006","unstructured":"Canbakan B, Senturk H, Tabak F, Akdogan M, Tahan V, Mert A, et al. Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: a randomized trial. J Gastroenterol Hepatol. 2006;21(4):657\u201363. https:\/\/doi.org\/10.1111\/j.1440-1746.2006.04082.x.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"693_CR93","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/j.1365-2893.2007.00936.x","volume":"15","author":"C Yurdaydin","year":"2008","unstructured":"Yurdaydin C, Bozkaya H, Onder FO, Sent\u00fcrk H, Karaaslan H, Akdo\u011fan M, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat. 2008;15(4):314\u201321. https:\/\/doi.org\/10.1111\/j.1365-2893.2007.00936.x.","journal-title":"J Viral Hepat"},{"issue":"6","key":"693_CR94","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1177\/135965350501000603","volume":"10","author":"F Gunsar","year":"2005","unstructured":"Gunsar F, Akarca US, Ersoz G, Kobak AC, Karasu Z, Yuce G, et al. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther. 2005;10(6):721\u20136.","journal-title":"Antivir Ther"},{"key":"693_CR95","doi-asserted-by":"publisher","first-page":"625","DOI":"10.4254\/wjh.v8.i14.625","volume":"8","author":"Z Abbas","year":"2016","unstructured":"Abbas Z, Memon MS, Umer MA, Abbas M, Shazi L. Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial. World J Hepatol. 2016;8:625\u201331.","journal-title":"World J Hepatol"},{"issue":"7","key":"693_CR96","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/QAD.0000000000001424","volume":"31","author":"V Soriano","year":"2017","unstructured":"Soriano V, Sherman KE, Barreiro P. Hepatitis delta and HIV infection. AIDS. 2017;31(7):875\u201384. https:\/\/doi.org\/10.1097\/QAD.0000000000001424.","journal-title":"AIDS"},{"key":"693_CR97","doi-asserted-by":"publisher","first-page":"e00049","DOI":"10.7554\/eLife.00049","volume":"1","author":"H Yan","year":"2012","unstructured":"Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012;1:e00049. https:\/\/doi.org\/10.7554\/eLife.00049.","journal-title":"Elife"},{"issue":"01","key":"693_CR98","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1055\/s-0037-1621711","volume":"38","author":"M Rizzetto","year":"2018","unstructured":"Rizzetto M. Targeting hepatitis D. Semin Liver Dis. 2018;38(01):66\u201372. https:\/\/doi.org\/10.1055\/s-0037-1621711.","journal-title":"Semin Liver Dis"},{"issue":"3","key":"693_CR99","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","volume":"65","author":"P Bogomolov","year":"2016","unstructured":"Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib\/IIa study. J Hepatol. 2016;65(3):490\u20138. https:\/\/doi.org\/10.1016\/j.jhep.2016.04.016.","journal-title":"J Hepatol"},{"key":"693_CR100","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0168-8278(18)30224-1","volume":"68","author":"H Wedemeyer","year":"2018","unstructured":"Wedemeyer H, Bogomolov P, Blank A, Allweiss L, Dandri-Petersen M, Bremer B, et al. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV\/HDV co-infection. J Hepatol. 2018;68:S3.","journal-title":"J Hepatol"},{"key":"693_CR101","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1016\/S0168-8278(18)30398-2","volume":"68","author":"L Allweiss","year":"2018","unstructured":"Allweiss L, Dettmer C, Volz T, Giersch K, Alexandrov A, Wedemeyer H, et al. Strong intrahepatic decline of hepatitis D virus RNA and antigen after 24 weeks of treatment with Myrcludex B in combinationwith Tenofovir in chronic HBV\/HDV infected patients: interim results from a multicenter, open-label phase 2b clinical trial. J Hepatol. 2018;68:S90. https:\/\/doi.org\/10.1016\/S0168-8278(18)30398-2.","journal-title":"J Hepatol"},{"key":"693_CR102","first-page":"910A","volume":"64","author":"C Yurdaydin","year":"2016","unstructured":"Yurdaydin C, Idilman R, Kalkan C, Karakaya F, Kartal AC, Keskin O, et al. Exploring optimal dosing of Lonafarnib with ritonavir for the treatment of chronic delta hepatitis-interim results from the lowr HDV-2 study. Hepatology. 2016;64:910A.","journal-title":"Hepatology"},{"key":"693_CR103","first-page":"16A","volume":"68","author":"H Wedemeyer","year":"2018","unstructured":"Wedemeyer H, Katrin Sch\u00f6neweis K, Bogomolov PO, Voronkova NV, Chulanov V, Stepanova T, et al. Interim results of a multicentre, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in combination with peg-interferon alpha 2a in patients with chronic HBV\/HDV co-infection. Hepatology. 2018;68:16A.","journal-title":"Hepatology"},{"key":"693_CR104","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","volume":"15","author":"C Koh","year":"2015","unstructured":"Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis. 2015;15:1167\u201374.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"693_CR105","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1124\/dmd.105.007906","volume":"34","author":"A Ghosal","year":"2006","unstructured":"Ghosal A, Chowdhury SK, Tong W, Hapangama N, Yuan Y, Su AD, et al. Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar). Drug Metab Dispos. 2006;34(4):628\u201335. https:\/\/doi.org\/10.1124\/dmd.105.007906.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"693_CR106","doi-asserted-by":"publisher","first-page":"121A","DOI":"10.1016\/S0168-8278(17)30310-0","volume":"64","author":"H Wedemeyer","year":"2016","unstructured":"Wedemeyer H, Port K, Deterding K, Wranke A, Kirschner J, Martins EB, et al. A phase 2 study of titrating dose lonafarnib plus ritonavir in patients with chronic hepatitis D: interim results from the lonafarnib with ritonavir in HDV-4 study. AASLD Hepatol. 2016;64(1):121A. https:\/\/doi.org\/10.1016\/S0168-8278(17)30310-0.","journal-title":"AASLD Hepatol"},{"key":"693_CR107","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1016\/S0168-8278(18)30397-0","volume":"68","author":"C Yurdaydin","year":"2018","unstructured":"Yurdaydin C, Kalkan C, Karakaya F, Caliskan A, Karatayli S, Keskin O, et al. Subanalysis of the LOWR HDV-2 study reveals high response rates to Lonafarnib in patients with low viral loads. J Hepatol. 2018;68:S89. https:\/\/doi.org\/10.1016\/S0168-8278(18)30397-0.","journal-title":"J Hepatol"},{"key":"693_CR108","doi-asserted-by":"publisher","first-page":"S509","DOI":"10.1016\/S0168-8278(18)31266-2","volume":"68","author":"M Bazinet","year":"2018","unstructured":"Bazinet M, Pantea V, Cebotarescu V, Cojuhari L, Jimbei P, Vaillant A. Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV\/HDV co-infection: 18 month follow-up results from the REP 301-LTF study. J Hepatol. 2018;68:S509. https:\/\/doi.org\/10.1016\/S0168-8278(18)31266-2.","journal-title":"J Hepatol"},{"key":"693_CR109","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","volume":"2","author":"M Bazinet","year":"2017","unstructured":"Bazinet M, P\u00e2ntea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, et al. Safety and efficacy of REP2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2017;2:877\u201389.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"693_CR110","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1055\/s-0032-1323628","volume":"32","author":"P Farci","year":"2012","unstructured":"Farci P, Niro GA. Clinical features of hepatitis D. Semin Liver Dis. 2012;32:228\u201336.","journal-title":"Semin Liver Dis"},{"issue":"2","key":"693_CR111","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/liv.13205","volume":"37","author":"GL Lutterkort","year":"2017","unstructured":"Lutterkort GL, Wranke A, Yurdaydin C, Budde E, Westphal M, Lichtinghagen R, et al. Non-invasive fibrosis score for hepatitis delta. Liver Int. 2017;37(2):196\u2013204. https:\/\/doi.org\/10.1111\/liv.13205.","journal-title":"Liver Int"},{"issue":"5","key":"693_CR112","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jhep.2018.12.022","volume":"70","author":"C Yurdaydin","year":"2019","unstructured":"Yurdaydin C, Abbas Z, Buti M, Cornberg M, Esteban R, Etzion O, et al. Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy. J Hepatol. 2019;70(5):1008\u201315. https:\/\/doi.org\/10.1016\/j.jhep.2018.12.022.","journal-title":"J Hepatol"}],"container-title":["Archives of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13690-021-00693-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13690-021-00693-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13690-021-00693-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T12:09:55Z","timestamp":1675771795000},"score":1,"resource":{"primary":{"URL":"https:\/\/archpublichealth.biomedcentral.com\/articles\/10.1186\/s13690-021-00693-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":112,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["693"],"URL":"https:\/\/doi.org\/10.1186\/s13690-021-00693-2","relation":{},"ISSN":["2049-3258"],"issn-type":[{"value":"2049-3258","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,19]]},"assertion":[{"value":"21 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Yurdaydin reports personal fees from Gilead Sciences BIOPHARMA, personal fees from Abbvie and, grants from Eiger, outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"180"}}